一个随机比较的基基化物,mometasone furoate,和一个组合,持久性过敏性鼻炎
Xian Li1, Xueyan Wang2, Qintai Yang3
1Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing, China; Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China; Beijing Laboratory of Allergic Diseases and Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.
The journal of allergy and clinical immunology. In practice
|January 2, 2025
概括
在过敏性鼻炎 (AR) 患者中,基化 (BCQB) 鼻喷剂有效减少了流鼻症的症状. 结合BCQB和mometasone furoate鼻喷雾剂 (MFNS),改善了总鼻腔症状得分,比单独使用MFNS更好.
科学领域:
- 过敏和免疫学 过敏和免疫学
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
- 临床药理学 临床药理学
背景情况:
- 中度至重度的持续性过敏性鼻炎 (AR) 显著影响生活质量,并造成重大社会经济成本.
- 目前对AR的治疗选择需要进一步优化,以有效地解决症状负担.
研究的目的:
- 为了评估本环基化物 (BCQB) 鼻喷雾与单独使用的莫梅酸鼻喷雾 (MFNS) 的优势.
- 评估BCQB和MFNS组合治疗与单独MFNS在中度至重度持久性AR的成年人中的疗效.
主要方法:
- 一个多中心,随机,受控的临床试验,涉及中度至重度持久性AR的成年人.
- 参与者接受了BCQB,MFNS或BCQB和MFNS的组合4周.
- 症状得分 (流鼻水,堵塞,打喷,,鼻腔症状总得分) 和生活质量 (犀牛结膜炎生活质量问卷) 是主要终点.
主要成果:
- 与单独使用MFNS相比,BCQB显著改善了每日流鼻症状 (P = .004).
- 与单独使用MFNS相比,BCQB和MFNS的组合显示出鼻水,鼻塞,打喷,鼻腔症状总得分和生活质量的显著改善.
- 治疗BCQB导致炎症标志物显著减少,包括埃索诺菲尔酸蛋白,eotaxin,血管活性肠和IL-6.
结论:
- 在缓解中度至严重的持续性过敏性鼻炎中流鼻症状方面,化鼻喷剂优于mometasone furoate鼻喷剂.
- 与BCQB和MFNS结合疗法在降低整体鼻腔症状负担和改善生活质量方面具有卓越的疗效,与MFNS单一疗法相比.
相关概念视频
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
217
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
217
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
236
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
236
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
231
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
231
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
225
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
225
01:28Adrenergic Agonists: Mixed-Action Agents
661
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
661